

## Enrofloxacin/BSA

|           |   |
|-----------|---|
| Cat. No.: | HY-161489   |
| Target:   | Antibiotic  |
| Pathway:  | Anti-infection  |
| Storage:  | Please store the product under the recommended conditions in the Certificate of Analysis. |

## Enrofloxacin/BSA

### BIOLOGICAL ACTIVITY

#### Description

Enrofloxacin/BSA is one of protein/peptide and small molecule drug conjugates (PDCs), consisting of Enrofloxacin (HY-B0502) and BSA. PDCs are promising targeted therapeutics with better cell permeability and drug selectivity than antibody-drug conjugates (ADCs). PDCs have been widely used in research on cancer, COVID-19, and metabolic diseases<sup>[1]</sup>.

### REFERENCES

[1]. Fu C, et al. Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope? Acta Pharm Sin B. 2023 Feb;13(2):498-516.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA